



CAPLIN POINT
Laboratories

Caplin Point Laboratories Limited

Regd. Off. : "NARBAVI" No. 3, Lakshmanan Street,
T.Nagar, Chennai - 600017. Tamil Nadu, India

Phone : +91 44 28156653, 28156901, 28156905, Fax : 28154952

E-mail : info@caplinpoint.net / Website : www.caplinpoint.net

CIN : L24231TN1990PLC019053

06.08.2018

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code : 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code : CAPLIPOINT.

By NEAPS

Dear Sirs,

SUB: OUTCOME OF THE BOARD MEETING

The Board of Directors of the Company at their meeting held today:

1. Approved the Un-audited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2018.
2. To convene the 27th Annual General Meeting of the Company on Friday, September 28, 2018 at 10.00 AM

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose:

1. Un-audited Financial results (Standalone and Consolidated) for the quarter ended June 30, 2018.
2. Limited Review Report (Standalone and Consolidated) for the above Un-audited Financial Results .

The Board meeting commenced at 11.30 AM and concluded at 2.00 P.M

Thanking You,

Yours Faithfully,
For Caplin Point Laboratories Limited

Company Secretary

Unit I : No. 85/3, Suthukeny Village, Mannadipet Commune, Puducherry - 605502. Ph.: 95242 32888 / 95242 32006

Unit II : No. 19, Chinnapuliur Village, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District - 601 201. Ph.: 9445391317

Unit IV : Survey No.: 895 & 897, Guruvarajakandigai, Sirupuzhalpettai (Post), Gummidipoondi Taluk, Thiruvallur District - 601 201. Ph.: 9788459333 / 69333

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 30th JUNE 2018

Prepared in compliance with the Indian Accounting Standards (Ind - AS)

| | Particulars | Three Months Ended | | | Financial Year Ended |
|--------------|--|--------------------|------------------|------------------|----------------------|
| | | 30.06.2018 | 31.03.2018 | 30.06.2017 | 31.03.2018 |
| | | (1) | (2) | (3) | (4) |
| | | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| INR In Lakhs | | | | | |
| | Income: | | | | |
| I | Revenue from operations | 12,516.28 | 11,044.13 | 10,189.20 | 42,657.39 |
| II | Other income Including dividend/share of profit from subsidiary/LLP | 1,805.49 | 306.83 | 386.21 | 2,331.33 |
| III | Total Income (I+II) | 14,321.77 | 11,350.96 | 10,575.41 | 44,988.72 |
| | Expenses: | | | | |
| IV | a. Cost of materials consumed | 2,364.99 | 2,079.47 | 2,025.24 | 9,021.63 |
| | b. Purchase of traded goods | 3,203.10 | 2,642.13 | 2,403.62 | 9,228.22 |
| | c. Changes in inventories of finished goods, stock in trade and work in progress | 2.99 | (266.80) | (39.33) | (238.77) |
| | d. Employee benefit expenses | 1,145.92 | 981.71 | 897.42 | 3,882.04 |
| | e. Finance cost | 1.22 | 1.36 | 1.61 | 6.12 |
| | f. Depreciation & Amortisation Expenses | 545.23 | 617.41 | 384.45 | 1,898.78 |
| | g. Other Expenses | 1,744.06 | 2,124.50 | 1,505.04 | 6,585.40 |
| | h. Total Expenses | 9,007.51 | 8,179.78 | 7,178.05 | 30,383.42 |
| V | Profit before exceptional items and Tax (IV-V) | 5,314.26 | 3,171.18 | 3,397.36 | 14,605.30 |
| VI | Exceptional items | - | - | - | - |
| VII | Profit Before Tax (V-VI) | 5,314.26 | 3,171.18 | 3,397.36 | 14,605.30 |
| VIII | Tax Expenses | | | | |
| | (1) Current Tax | 948.55 | 1,014.31 | 883.63 | 4,054.79 |
| | (2) Deferred Tax | 229.46 | (0.94) | 73.99 | 319.42 |
| | Total Tax Expenses | 1,178.01 | 1,013.37 | 957.62 | 4,374.21 |
| IX | Net Profit for the period (VII-VIII) | 4,136.25 | 2,157.81 | 2,439.74 | 10,231.09 |
| X | Other Comprehensive Income/ (Loss) - Net of Income Tax | | | | |
| | A. Items that will not be re-classified to profit or loss | | | | |
| | i) Remeasurements of Defined Benefit Plan | 14.05 | 64.23 | 4.13 | 76.60 |
| XI | Total Comprehensive Income For The Period (IX+X) | 4,150.30 | 2,222.04 | 2,443.87 | 10,307.69 |
| XII | Paid up Equity Share Capital (Face value of shares of Rs 2/- each) | 1,512.07 | 1,512.07 | 1,511.53 | 1,512.07 |
| XIII | Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year | | | | 28,048.36 |
| XIV | Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share | | | | |
| | (a) Basic (in Rupees) | 5.47 | 2.94 | 3.23 | 13.64 |
| | (b) Diluted (in Rupees) | 5.45 | 2.93 | 3.21 | 13.57 |



Indhan



Notes :

- 1) This statement has been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The above results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meeting held on 6th August 2018.
- 3) The Other income for the three months period ended 30 June 2018 includes a dividend income of Rs 1648.03 lakhs from 100% foreign subsidiary in Hong Kong which has an impact on the earnings and EPS.
- 4) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 5) The statutory auditors have carried out a limited review of the stand alone results for the quarter ended 30th June 2018.
- 6) Prior year / period figures are regrouped / rearranged wherever necessary.



Dr Sridhar Ganesan
Managing Director

Place : Chennai
Date : 6th August 2018





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

S. NEELAKANTAN
B.Com., FCA

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

R. THIRUMALMARUGAN
M.Com., FCA

K. PARTHASARATHY
B.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

V. VIVEK ANAND
B.Com., FCA

E.K. SRIVATSAN
B.Com., FCA


Limited Review Report on Quarterly Standalone Financials Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
CAPLIN POINT LABORATORIES LIMITED, CHENNAI-600017

1. We have reviewed the accompanying statement of unaudited Standalone financial results of **Caplin Point Laboratories Limited** ("the company") for the quarter ended June 30,2018 ("the statements"). The Statement has been prepared by the company pursuant to Regulation 33 of the SBEI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This statement is the responsibility of the Company Management and approved by the Board of Directors. Our responsibility is to express an opinion on the statement.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A Review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results has not been prepared in all material respects in accordance with applicable Accounting standards prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For CNGSN & ASSOCIATES LLP
Chartered Accountants
Firm Registration No. 004915S /S200036


K. Parthasarathy
Partner

Place: Chennai

Date: August 6, 2018

(Membership No. 018394)

CAPLIN POINT LABORATORIES LIMITED

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennai 600 017

CIN - L24231TN1990PLC019053, Phone Nos.044-28156653,28156905, Fax No.044-28154952, Website - www.caplinpoint.net, email ID-info@caplinpoint.net

UNAUDITED (CONSOLIDATED) FINANCIAL RESULTS FOR THE THREE MONTHS ENDED 30th JUNE 2018

Prepared in compliance with the Indian Accounting Standards (Ind - AS)


| Particulars | Three Months ended | | | Financial Year Ended |
|--|--------------------|------------------|------------------|----------------------|
| | 30.06.2018 | 31.03. 2018 | 30.06.2017 | 31.03.2018 |
| | (1) | (2) | (3) | (4) |
| | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| | INR in lakhs | | | |
| Income: | | | | |
| I Revenue from operations | 14,645.99 | 14341.08 | 12,351.18 | 53,984.20 |
| II Other income | 160.93 | 289.86 | 386.21 | 1,266.52 |
| III Total Income (I+II) | 14,806.92 | 14630.94 | 12,737.39 | 55,250.72 |
| IV Expenses: | | | | |
| a. Cost of materials consumed | 2,364.99 | 2,079.47 | 2,025.24 | 9,021.63 |
| b. Purchase of traded goods | 4,041.29 | 4,406.01 | 3,364.89 | 15,035.10 |
| c. Changes in inventories of finished goods, stock in trade and work in progress | 2.99 | (266.80) | (39.33) | (238.77) |
| d. Employee benefit expenses | 1,152.40 | 1,013.94 | 897.42 | 3,914.27 |
| e. Finance cost | 1.22 | 1.36 | 1.61 | 6.12 |
| f. Depreciation & Amortisation Expenses | 545.33 | 617.57 | 384.45 | 1,899.50 |
| g. Other Expenses | 1,781.28 | 2,236.57 | 1,513.04 | 6,775.04 |
| h. Total Expenses | 9,889.50 | 10,088.12 | 8,147.32 | 36,412.89 |
| V Profit before exceptional items and Tax (III-IV) | 4,917.42 | 4,542.82 | 4,590.07 | 18,837.83 |
| VI Exceptional items | - | - | - | - |
| VII Profit Before Tax (V-VI) | 4,917.42 | 4,542.82 | 4,590.07 | 18,837.83 |
| VIII Tax Expenses | | | | |
| (1) Current Tax | 948.55 | 1,014.43 | 883.63 | 4,054.91 |
| (2) Deferred Tax | 229.46 | (0.94) | 73.99 | 319.42 |
| Total Tax Expenses | 1,178.01 | 1,013.49 | 957.62 | 4,374.33 |
| IX Net Profit for the period (VII - VIII) | 3,739.41 | 3,529.33 | 3,632.45 | 14,463.50 |
| X Other Comprehensive Income - Net of Income Tax | | | | |
| A. Items that will not be re-classified to profit or loss | | | | |
| i) Remeasurements of Defined Benefit Plan | 14.05 | 64.23 | 4.13 | 76.60 |
| B. Items that will be re-classified to profit or loss | | | | |
| i) Exchange difference in translating the financial statements of foreign operations | (10.42) | - | - | - |
| XI Total Comprehensive Income For The Period (IX + X) | 3,743.04 | 3,593.56 | 3,636.58 | 14,540.10 |
| XII Profit attributable to: | | | | |
| Owners of the Company | 3,742.90 | 3,535.78 | 3,633.32 | 14,478.77 |
| Non- controlling interests | (3.49) | (6.45) | (0.87) | (15.27) |
| | 3,739.41 | 3,529.33 | 3,632.45 | 14,463.50 |
| XIII Total Comprehensive Income For The Period attributable to | | | | |
| Owners of the Company | 3,746.53 | 3,600.01 | 3,637.45 | 14,555.37 |
| Non- controlling interests | (3.49) | (6.45) | (0.87) | (15.27) |
| | 3,743.04 | 3,593.56 | 3,636.58 | 14,540.10 |
| XIV Paid up Equity Share Capital (Face value of share of Rs 2/- each) | 1,512.07 | 1,512.07 | 1,511.53 | 1,512.07 |
| XV Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year | | | | 34,871.08 |
| XVI Earnings Per Share (EPS) (Not annualised) based on face value Rs 2/- per Equity share | | | | |
| (a) Basic (in Rupees) | 4.95 | 4.76 | 4.81 | 19.26 |
| (b) Diluted (in Rupees) | 4.92 | 4.74 | 4.79 | 19.16 |



Notes :

- 1) This statement has been prepared in accordance with the Companies (Indian Accounting standards) Rules, 2015 ("Ind As") prescribed under Section 133 of the Companies Act, 2013 and other accounting pronouncement generally accepted in India, to the extent applicable.
- 2) The above results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meeting held on 6th August 2018.
- 3) The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals formulations". There is no exceptional and/or extra ordinary item.
- 4) The statutory auditors have carried out a limited review of the consolidated results for the quarter ended 30th June 2018.
- 5) Prior year / period figures are regrouped / rearranged wherever necessary.

Place Chennai
Date 6th August 2018



Dr Sridhar Ganesan
Managing Director





CNGSN & ASSOCIATES LLP

CHARTERED ACCOUNTANTS

Swathi Court, Flat No. C & D, No. 43, (Old No. 22)
Vijayaraghava Road, T. Nagar, Chennai - 600 017.
Tel : +91-44-4554 1480 / 81; Fax : +91-44-4554 1482
Web : www.cngsn.com ; Email : info@cngsn.com

Dr. C.N. GANGADARAN
B.Com., FCA, MBIM (Lond.), Ph.d.

CHINNSAMY GANESAN
B.Com., FCA, DISA (ICAI)

S. NEELAKANTAN
B.Com., FCA

D. KALAIALAGAN
B.Com., FCA, DISA (ICAI)

R. THIRUMALMARUGAN
M.Com., FCA

K. PARTHASARATHY
B.Com., FCA

B. RAMAKRISHNAN
B.Com., Grad. CWA, FCA

NYAPATHY SRILATHA
M.Com., FCA, PGDFM

V. VIVEK ANAND
B.Com., FCA

E.K. SRIVATSAN
B.Com., FCA

Limited Review Report on Quarterly Consolidated Financials Results of Caplin Point Laboratories Limited pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
CAPLIN POINT LABORATORIES LIMITED, CHENNAI-600017

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Caplin Point Laboratories Limited ("the company") and its subsidiaries (the company and its subsidiaries constitute "the group") for the quarter ended June 30, 2018, ("the statements"). The Statement has been prepared by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This statement is the responsibility of the Company Management and approved by the Board of Directors. Our responsibility is to express an opinion on the statement.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A Review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.


The Statements includes the results of the following entities:

- a) Argus Salud Pharma LLP
- b) Caplin Point Far East Limited
- c) Caplin Point Laboratories Colombia SAS

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results has not been prepared in all material respects in accordance with applicable Accounting standards prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For CNGSN & ASSOCIATES LLP
Chartered Accountants
Firm Registration No. 004915S /S200036


K. Parthasarathy
Partner
(Membership No. 018394)

Place: Chennai
Date: August 6, 2018